Breathing Better: Scaling up EU Prevention Policies for Respiratory Health
Breathing Better: Scaling up EU Prevention Policies for Respiratory Health Report from the EU Parliament event, September 23, 2025
Report from the world PH Symposium Updates 2025
This event was organized as an interim update to the World Symposium on Pulmonary Hypertension (WSPH), which has traditionally been held every five years.
PVRI Symposium Report 2025
I recently attended the PVRI Drug Discovery & Development Symposium 2025 in Amsterdam, held 16–17 June and regarded as the smaller of PVRI’s two Hlagship meetings.
PHAEUROPE at the European Parliament: Advocating for Better Lung Health
On February 4th and 5th, I hade the privilege to represent PHAEUROPE in two significant events at the European Parliament - the Healthy Lungs for Life exhibition and EFA’s event on raising standards of COPD care.
EMA Approves WINREVAIR (Sotatercept) for Treatment of PAH
PHA Europe is pleased to share the exciting news that the European Medicines Agency (EMA) has approved WINREVAIR™ (sotatercept) for the treatment of Pulmonary Arterial Hypertension (PAH).
Report from the International PHA conference
PHA recently held its 15th international PH conference in Indianapolis, Indiana. This gathering brought together a diverse group of about 1100 healthcare professionals, researchers, patients, and advocates from around the world, all united by a shared commitment to advancing the understanding and treatment of pulmonary
TORREY results in Lancet
The pharmaceutical company Gossamer Bio, celebrates a significant achievement with the publication of its TORREY Phase 2 study results in the esteemed Lancet Respiratory Medicine journal.
Report from IMPAHCT 2024
Approximately 150 pulmonary hypertension (PH) specialists convened in Barcelona in April 2024 for Ferrer’s 6th edition of the IMPAHCT meeting. Notably, Hall Skaara represented PHA Europe for the second time at the conference, serving as the sole patient advocate present.
FDA recently approved Opsynvi
The FDA recently approved Opsynvi, developed by Johnson & Johnson, for treating pulmonary arterial hypertension (PAH) in adults, marking a significant advancement in PAH management.
Sotatercept approved by FDA
Merck, also known as MSD outside of the United States and Canada, has announced the FDA approval of Winrevair™ (sotatercept), a groundbreaking biologic for the treatment of adults with pulmonary arterial hypertension (PAH).
Report from SAPH2024
The Saudi Association for Pulmonary Hypertension (SAPH) hosted its 17th annual conference in Riyadh, Saudi Arabia, from February 15 to 17, 2024. The conference featured an impressive scientific program with sessions led by numerous leading PH specialists from around the world.
Report from the IMPACHT conference in Barcelona June 30th – July 1st
Ferrer annually hosts a conference known as IMPACHT (International Meeting on Pulmonary Hypertension Clinical Treatment) that caters to pulmonologists and cardiologists.
APHEC 2022
Due to the COVID pandemic, the annual PH European conference (APHEC) had to be run virtually. This has worked very well as we utilised an excellent online platform where we rebuild our conference hotel in Barcelona.
Invitation to PHA Europe’s virtual annual conference (APHEC) – 2021
Our conference hall is now available. Here you will be able to see presentations by leading PH specialist from last year’s conference and the presentations for this year’s conference will be available during the month of February. A wide range of topics are covered from